Send to a friend

The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.

The race to be first to develop a vaccine for AIDS could have dire consequences, argues John P. Moore, who says that the competitive mentality of US federal agencies is leading to the wasteful duplication of effort.

Despite claims to the contrary, the present generation of AIDS vaccine candidates will in all probability be of little benefit to populations in the developing world.

The price of failure in a string of trials will be costly — the erosion of public confidence in science’s ability to deliver an effective HIV-1 vaccine.

Link to full text

Reference: Nature 415, 365 (2002)